Proactive Investors - Run By Investors For Investors

e-Therapeutics eyes further partnerships and possibly M&A to fully exploit its potential

Its most significant landmark of the year just gone was a collaboration with Danish multi-national Novo Nordisk focusing on type-2 diabetes
The company is at the forefront of network-driven drug discovery

e-Therapeutics PLC’s (LON:ETX) annual results revealed a year of significant progress exploiting the potential of its network-driven drug discovery, including its first commercial research collaboration.

That particular tie-up, with the Danish multi-national Novo Nordisk focusing on type-2 diabetes, provided “important validation” of its technology, the company said.

It added that business development activities continued with “a number of discussions progressing on a range of revenue-generating and value-creating deals”.

READ: Danish drugs giant Novo Nordisk to use e-Therapeutics’ technology in searchfor new diabetes treatments

Interestingly, chairman Iain Ross said his team was looking at “alternative sources of funding”, broader industry partnerships and potentially M&A deals “in order to fully exploit all [e-Therapeutics’] assets and capabilities”.

The life sciences group said the current partnerships with companies such as C4X Discovery, Biorelate and Intellegens were “delivering”. Meanwhile, in-house work on patient work in breast cancer has yielded “promising results”.

In common with most businesses at this formative stage of development, e-Therapeutics was loss-making. It posted a £5.1mln operating deficit for the 12 months to the end of January as it burned £3.7mln in cash. More importantly, it was sitting on funds of £5.9mln as at the year-end.

“In executing our plans, we have managed our cash and resources carefully to nurture our core business and to enable us to continue to offer a range of assets and capabilities to the industry,” said chief executive Ray Barlow.

“We remain focused on our extensive business development efforts and are in a number of detailed discussions with potential partners.

“Confident in the broad versatility and utility of the NDD platform, we remain focused on translating this into value for our shareholders."

View full ETX profile View Profile

e-Therapeutics plc Timeline

Research Video
March 28 2018

Related Articles

copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences
A stomach adenocarcinoma
February 12 2019
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage study.
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use